The Acceleration of Glucose Accumulation in Renal Cell Carcinoma Assessed by FDG PET/CT Demonstrated Acquisition of Resistance to Tyrosine Kinase Inhibitor Therapy

BMC Cancer - United Kingdom
doi 10.1186/s12885-016-3044-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations

Frontiers in Oncology
Cancer ResearchOncology
2016English

Meta-Analysis of the Diagnostic Performance of [18f]fdg-Pet and PET/CT in Renal Cell Carcinoma

Cancer Imaging
Nuclear MedicineRadiologyUltrasound TechnologyOncologyRadiologicalImagingMedicine
2012English

Role of F18-FDG-Pet/Ct in Restaging Patients Affected by Renal Carcinoma

Nuclear Medicine Review
MedicineNuclear MedicineRadiologyImaging
2013English

FDG PET/CT in Carcinoma of Unknown Primary

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2009English

Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma

PLoS ONE
Multidisciplinary
2016English

The Expression and Role of Tyrosine Kinase ETK/BMX in Renal Cell Carcinoma

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2014English

Brain Metastases From Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors

Clinical Genitourinary Cancer
OncologyUrology
2013English

Personalized Therapy in Renal Cell Carcinoma: Are the Different Tyrosine Kinase Inhibitors the Same for Any Patient?

Expert Review of Precision Medicine and Drug Development
Molecular MedicineDrug DiscoveryGeneticsPharmacology
2017English

Mp20-15 Comparison Between 68 Ga-Labelled Psma and 18 F-FDG Pet/Ct in the Diagnostic Value of Clear Cell Renal Cell Carcinoma

Journal of Urology
Urology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy